

From: SANTE CONSULT-C1
Sent: jeudi 20 mai 2021 17:05
To: [REDACTED] (SANTE)
Cc: SANTE CONSULT-C1
Subject: FW: Our call - question regarding press release of May 6

From: [REDACTED] <[\[REDACTED\]@mc-services.eu](mailto:[REDACTED]@mc-services.eu)>
Date: Monday, 10 May 2021 at 11:56:21
To: [REDACTED] (COMM)" - [REDACTED]
[REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>
Subject: Our call - question regarding press release of May 6

Dear [REDACTED]

Nice talking to you.

MC Services is a life science focused PR consultancy working for a variety of European pharma and biotech companies, many of them focusing on COVID-19 therapeutics.

Reading your press release of May 6, 2021, we and our clients asked ourselves the question how a company can apply for the program that is targeted at authorizing three new therapeutics to treat COVID-19 by October 2021.

If you could advice that would be greatly appreciated.

Kind regards



MC Services AG
Kaiser-Friedrich-Ring 5
40545 Düsseldorf

phone: +49 [REDACTED]
mobile: +49 [REDACTED]
fax: +49 [REDACTED]
email: [REDACTED] <[\[REDACTED\]@mc-services.eu](mailto:[REDACTED]@mc-services.eu)>

www.mc-services.eu

MC Services AG

Handelsregister/Commercial Register: Amtsgericht Augsburg HRB 2117

Vorstand/Management Board:

Aufsichtsrat/Supervisory Board:

This message may contain confidential and/or privileged information. If you are not the addressee or authorized to receive this for the addressee, you must not use, copy, disclose or take any action based on this message or any information herein. If you have received this message in error, please advise the sender immediately by reply e-mail and delete this message. Thank you for your cooperation.